Generics - North America, Cardio-vascular

Filter

Popular Filters

1 to 25 of 34 results

Actavis challenges Multaq and Colcrys patents

02-03-2014

Ireland-headquartered generic drugmaker Actavis revealed on Friday (February 28) that French pharma giant…

ActavisAnti-Arthritics/RheumaticsCardio-vascularColcrysGenericsLegalMultaqNorth AmericaPatents & Trade marksRegulationSanofiTakeda PharmaceuticalsUSA

Forest Labs settles Bystolic litigation with Actavis

07-11-2013

US drugmaker Forest Laboratories has entered into a settlement agreement with generics drug major Actavis…

ActavisBystolicCardio-vascularForest LaboratoriesGenericsLegalNorth AmericaPatents

US Appeals Court reverses 2012 decision on Lovaza, clearing way for generics

13-09-2013

Reversing a district court decision last year (The Pharma Letter May 30, 2012), the US Court of Appeals…

AmarinCardio-vascularGenericsGlaxoSmithKlineLegalLovazaNorth AmericaPar PharmaceuticalsPatentsPharmaceuticalTeva Pharmaceutical IndustriesVascepa

Forest agrees another license deal for Bystolic

22-07-2013

US drugmaker Forest Laboratories (NYSE:FRX) and Forest Laboratories Holdings have reached a settlement…

Amerigen PharmaceuticalsBystolicCardio-vascularForest LaboratoriesGenericsLicensingNorth AmericaPharmaceutical

Generic versions of Trilipix debut in USA; Mylan sued by UCB

16-07-2013

Impax Laboratories (Nasdaq: IPXL) today announced yesterday (July 15) that it is commencing shipment…

AbbVieCardio-vascularGenericsImpax LaboratoriesLegalMarkets & MarketingMylan LaboratoriesNeurologicalNorth AmericaPatentsTripilixUCBVimpat

Impax launches authorized generic of Zomig, as Mylan debuts copy of Tricor in USA

20-05-2013

US drugmaker Impax Laboratories (Nasdaq: IPXL) says that its generics division, Global Pharmaceuticals,…

AbbVieAstraZenecaCardio-vascularGenericsImpax LaboratoriesMarkets & MarketingMylan LaboratoriesNeurologicalNorth AmericaTricorZomig

Adherence to generic cholesterol-lowering drugs linked to fall in total care costs

04-04-2013

People who regularly take statins to reduce high cholesterol will see lower hospitalization rates according…

Cardio-vascularFinancialGenericsMarkets & MarketingNorth America

AstraZeneca in Crestor patent settlement with Actavis and EGIS Pharma

25-03-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) has entered into a settlement agreement in its US patent…

ActavisCardio-vascularCrestorGenericsNorth AmericaPatentsPharmaceuticalrosuvastatinShionogiWatson Pharmaceuticals

Prescription drug costs: USA versus UK

04-11-2012

In the USA, the cost paid for statins (drugs to lower cholesterol) in people under the age of 65 who…

Cardio-vascularEuropeGastro-intestinalsGenericsNorth AmericaPharmaceuticalPricing

Watson gets FDA approval for generic Sanctura XR and Avapro

14-10-2012

US generic drugmaker Watson Pharmaceuticals (NYSE: WPI) has received approval from the US Food and Drug…

AllerganAvaproCardio-vascularGenericsGenito-urinaryNorth AmericaRegulationSanctura XRSanofiWatson Pharmaceuticals

Mylan debuts first generic Diovan HCT and Antivert copy in USA

23-09-2012

US generic drugmaker Mylan (Nasdaq: MYL) last Friday received final approval from the US Food and Drug…

AntivertCardio-vascularDiovan HCTGenericsMarkets & MarketingMylan LaboratoriesNeurologicalNorth AmericaNovartisPfizerRegulation

Wockhardt generic versions of Pfizer's Geodon and AstraZeneca's Plendil OKed by FDA

23-08-2012

Wockhardt generic versions of Pfizer's Geodon and AstraZeneca's Plendil OKed by FDA

AstraZenecaCardio-vascularGenericsGeodonMarkets & MarketingNeurologicalNorth AmericaPfizerPlendilRegulationWockhardt

USA FDA approves ANDAs for Plan B One-Step and Trandate

16-07-2012

Watson Pharmaceuticals (NYSE: WPI) says its subsidiary Watson Laboratories approval from the US Food…

Cardio-vascularGenericsNorth AmericaPar PharmaceuticalsPlan B One-StepRegulationReproductiveTeva Pharmaceutical IndustriesTrandateWatson Pharmaceuticals

No observable difference between generic and branded statins in preventing CV events; study

05-06-2012

People taking the most commonly used generic and branded statins to control their cholesterol had similar…

Cardio-vascularGenericsNorth AmericaPharmaceuticalPricing

US FDA approves generic versions of blood thinner Plavix

18-05-2012

Coinciding with the loss of patent protection on Sanofi (Euronext: SAN) and Bristol-Myers Squibb's (NYSE:…

Cardio-vascularClopidogrelDr Reddy's LaboratoriesGenericsMylan LaboratoriesNorth AmericaPlavixRegulation

Mylan debuts Lescol copy; Impax challenges Gralise patent

16-04-2012

US generic drug major Mylan (Nasdaq: MYL) revealed last Friday that it has begun shipping its generic…

Cardio-vascularDepomedGenericsGraliseImpax LaboratoriesLescolMarkets & MarketingMylan LaboratoriesNeurologicalNorth AmericaNovartisPatentsRegulation

Watson confirms Abbott Niaspan patent challenge

19-03-2012

USA-based Watson Pharmaceuticals (NYSE: WPI) has confirmed that its subsidiary, Watson Laboratories,…

Abbott LaboratoriesCardio-vascularGenericsNiaspanNorth AmericaPatentsWatson Pharmaceuticals

Mylan gets OK for generic Crestor in Canada; Rottapharm deal looks dead

18-03-2012

The Canadian subsidiary of US generic drugmaker Mylan (Nasdaq: MYL) has received approval from Health…

AstraZenecaCardio-vascularCrestorEuropeGenericsMergers & AcquisitionsMylan LaboratoriesNorth AmericaPharmaceuticalRegulationRottapharm

United Therapeutics sues Sandoz over Remodulin patent infringement

16-03-2012

United Therapeutics (Nasdaq: UTHR) says that it has filed a law suit in the US District Court for the…

Cardio-vascularGenericsLegalNorth AmericaNovartisPatentsPharmaceuticalRemodulinSandozUnited Therapeutics

1 to 25 of 34 results

Back to top